Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $400000.0.

  • Pliant Therapeutics' Depreciation & Amortization (CF) fell 2000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 1854.92%. This contributed to the annual value of $2.1 million for FY2024, which is 1542.64% up from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' Depreciation & Amortization (CF) is $400000.0, which was down 2000.0% from $400000.0 recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Depreciation & Amortization (CF) ranged from a high of $600000.0 in Q2 2024 and a low of $400000.0 during Q1 2021
  • For the 5-year period, Pliant Therapeutics' Depreciation & Amortization (CF) averaged around $450947.4, with its median value being $425000.0 (2024).
  • As far as peak fluctuations go, Pliant Therapeutics' Depreciation & Amortization (CF) skyrocketed by 5000.0% in 2024, and later tumbled by 3333.33% in 2025.
  • Pliant Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $418000.0 in 2021, then increased by 1.2% to $423000.0 in 2022, then increased by 4.26% to $441000.0 in 2023, then decreased by 3.63% to $425000.0 in 2024, then decreased by 5.88% to $400000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $400000.0 in Q3 2025, compared to $400000.0 in Q2 2025 and $448000.0 in Q1 2025.